Current
74.5×
5-Year Average
74.1×
All-Time High
157.2×
All-Time Low
19.1×
P/E Ratio daily chart for Bio-Techne (TECH)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/E Ratio for Bio-Techne (TECH) from 2002 to 2025
| 2025 | $7.97B | $73.40M | 108.6× | +41.3× | |
| 2024 | $11.30B | $168.10M | 67.2× | +22.2× | |
| 2023 | $12.86B | $285.26M | 45.1× | -4.9× | |
| 2022 | $13.59B | $272.05M | 49.9× | -74.8× | |
| 2021 | $17.52B | $140.41M | 124.8× | +80.7× | |
| 2020 | $10.12B | $229.30M | 44.1× | -38.4× | |
| 2019 | $7.93B | $96.07M | 82.5× | +38.2× | |
| 2018 | $5.56B | $125.35M | 44.4× | -15.9× | |
| 2017 | $4.39B | $72.80M | 60.3× | +20.1× | |
| 2016 | $4.20B | $104.47M | 40.2× | +6.2× | |
| 2015 | $3.66B | $107.73M | 34.0× | +3.1× | |
| 2014 | $3.42B | $110.95M | 30.9× | +8.1× | |
| 2013 | $2.57B | $112.56M | 22.8× | -1.5× | |
| 2012 | $2.73B | $112.33M | 24.3× | -3.2× | |
| 2011 | $3.09B | $112.30M | 27.5× | +8.2× | |
| 2010 | $2.13B | $109.78M | 19.4× | -3.2× | |
| 2009 | $2.38B | $105.24M | 22.6× | -6.3× | |
| 2008 | $2.99B | $103.56M | 28.9× | +2.3× | |
| 2007 | $2.26B | $85.11M | 26.5× | -0.8× | |
| 2006 | $2.01B | $73.35M | 27.3× | +0.4× | |
| 2005 | $1.78B | $66.13M | 26.9× | -6.9× | |
| 2004 | $1.79B | $52.93M | 33.8× | +6.4× | |
| 2003 | $1.24B | $45.40M | 27.4× | -15.0× | |
| 2002 | $1.15B | $27.13M | 42.4× | — |
- 2025108.6×
- 202467.2×
- 202345.1×
- 202249.9×
- 2021124.8×
- 202044.1×
- 201982.5×
- 201844.4×
- 201760.3×
- 201640.2×
- 201534.0×
- 201430.9×
- 201322.8×
- 201224.3×
- 201127.5×
- 201019.4×
- 200922.6×
- 200828.9×
- 200726.5×
- 200627.3×
- 200526.9×
- 200433.8×
- 200327.4×
- 200242.4×
About P/E Ratio at Bio-Techne (TECH)
Bio-Techne (TECH) P/E ratio is 74.5× as of June 5, 2026. The 5-year average is 74.1×. The sector median currently stands at 25.0×. The current ratio is at the 62th percentile of its own 10-year history.
Bio-Techne (TECH) historical P/E ratio has ranged from a low of 19.1× (2009) to a high of 157.2× (2021) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Bio-Techne P/E Ratio by Year
Bio-Techne P/E Ratio 2025: 108.6×
Bio-Techne (TECH) P/E ratio in 2025 was 108.6×, expanded from 67.2× the prior year.
Bio-Techne P/E Ratio 2024: 67.2×
Bio-Techne (TECH) P/E ratio in 2024 was 67.2×, expanded from 45.1× the prior year.
Bio-Techne P/E Ratio 2023: 45.1×
Bio-Techne (TECH) P/E ratio in 2023 was 45.1×, contracted from 49.9× the prior year.
Bio-Techne P/E Ratio 2022: 49.9×
Bio-Techne (TECH) P/E ratio in 2022 was 49.9×, contracted from 124.8× the prior year.
Bio-Techne P/E Ratio 2021: 124.8×
Bio-Techne (TECH) P/E ratio in 2021 was 124.8×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Bio-Techne (TECH), ranked by P/E ratio.
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Bio-Techne (TECH) Key Financials
Charts, filings, and peer comparison for every metric